CancerVax is pioneering a novel Universal Cancer Treatment Platform that leverages the body's immune system to specifically target and eliminate cancer cells. The company's innovative approach involves disguising cancer cells to resemble well-immunized diseases, such as measles and chickenpox, thereby tricking the immune system into recognizing and attacking them. This method aims to enhance the precision of cancer treatment by ensuring that only cancer cells are marked for destruction, which could significantly reduce the harmful side effects typically associated with conventional cancer therapies.

In addition to its unique cancer cell targeting strategy, CancerVax is developing Smart mRNA Technology, which is designed to detect, mark, and kill cancer cells while sparing healthy cells. This technology utilizes customizable nanoparticles that can be tailored to individual patient needs, potentially transforming cancer treatment into a more straightforward process akin to receiving a vaccination. The company is also collaborating with leading cancer researchers and institutions, such as UCLA, to refine its treatment methodologies and validate its hypotheses through advanced research and clinical models.

United States

CancerVAX is a drug development company focused on developing novel therapeutics in the oncology space. In partnership with the UCLA School of Medicine, we are progressing two programs: 1) Ewing sarcoma; 2) Universal cancer vaccine. CancerVAX is privately funded

CancerVax

Company Details